Fund Overview
Key Personnel
Activity Summary — 2025 Q4
Top Buys
| Stock | % Impact |
|---|---|
| ABVX ABIVAX SA.. | +4.56% |
| RNA AVIDITY BIOSCIE.. | +2.68% |
| IMVT IMMUNOVANT INC.. | +1.95% |
| PTGX PROTAGONIST THE.. | +1.88% |
| ROIV ROIVANT SCIENCE.. | +1.72% |
| TERN TERNS PHARMACEU.. | +1.58% |
Top Sells
| Stock | % Impact |
|---|---|
| KROS KEROS THERAPEUT.. | -6.15% |
| ETNB 89BIO INC.. Sold All 😨 Was: 2.92% | -2.25% |
| BIOA BIOAGE LABS INC.. | -0.67% |
| MTSR METSERA INC.. Sold All 😨 Was: 0.75% | -0.58% |
| RZLT REZOLUTE INC.. | -0.55% |
| ZLAB ZAI LAB LTD.. | -0.54% |
Activity Summary
Sector Allocation Trends
Holdings Analysis
Positions Dynamics
Portfolio Analytics — Latest
Tracking institutional benchmark deviation
Best Strategy vs. Benchmarks
Strategy Backtester: ADAR1 Capital Management, LLC
Replicate top holdings performance • Compare vs benchmarks • Optimize N
Find the best N! Test multiple portfolio sizes at once to discover the optimal configuration.
Risk insights! Identify periods when the fund lagged the benchmark – critical for timing entries.
⏱ Run Backtest
Liquid Glass Edition
👆 Click the button to launch tickers!
Disclaimer: 13Foresight is not a registered investment adviser, broker-dealer, or financial planner. All information on this site is provided solely for informational and educational purposes and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. Portfolio backtests shown on this page are hypothetical and simulated — they do not represent actual trading results and were constructed with the benefit of hindsight. Actual results would differ materially. 13F filings disclose only long equity positions valued above $10,000, submitted up to 45 days after quarter-end; they do not capture short positions, options, bonds, cash, private investments, or non-U.S. securities. A fund's backtest performance may not reflect its actual returns, as managers frequently generate alpha through strategies not visible in 13F data. Past performance is not indicative of future results. All data sourced from public SEC EDGAR filings. Use at your own risk. Full Terms of Use.